Circulation times in the splanchnic and hepatic beds in alcoholic liver disease

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Journal of human hypertension·2012

Rationale for angiotensin II receptor blocker therapy in chronic heart failure.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2007

Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.

Journal of human hypertension·2005

Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD).

Vascular medicine (London, England)·2002

Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

Gut·2002

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

The New England journal of medicine·2002

Global burden of liver disease: 2026 update.

Gastroenterology·2026

Dietary modulation of intestinal microbes prolongs survival in a Hirschsprung disease mouse model.

Gastroenterology·2026

Faecalibacterium prausnitzii EXL01 Strain for the prevention of multiple-recurrent Clostridioides difficile Infection.

Gastroenterology·2026

Short-Term Success, Long-Term Failure: Strain Turnover and Virulence Re-Emergence May Drive Relapse in Pouchitis.

Gastroenterology·2026

The dynamic trajectory of circulating exosome components in high-fat diet-induced metabolic-associated steatotic liver disease and its modulation by curcuminoids.

Frontiers in endocrinology·2026

Proteolytic remodeling by Yme1 enables mitochondrial-derived compartment formation.

bioRxiv : the preprint server for biology·2026

Genetically predicted ZDHHC8 expression and osteoporosis risk: A two-sample Mendelian randomization and metabolite mediation study.

Medicine·2026

Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Veterinary sciences·2026

Oxidative Stress as a Pathophysiological Core of Obesity: Preclinical Evidence for Antioxidant-Based Therapy Strategies.

Pharmaceuticals (Basel, Switzerland)·2026

Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.

Pharmaceuticals (Basel, Switzerland)·2026

Related Experiment Videos

Circulation times in the splanchnic and hepatic beds in alcoholic liver disease

Related Concept Videos

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Rationale for angiotensin II receptor blocker therapy in chronic heart failure.

Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.

Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD).

Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Global burden of liver disease: 2026 update.

Dietary modulation of intestinal microbes prolongs survival in a Hirschsprung disease mouse model.

Faecalibacterium prausnitzii EXL01 Strain for the prevention of multiple-recurrent Clostridioides difficile Infection.

Short-Term Success, Long-Term Failure: Strain Turnover and Virulence Re-Emergence May Drive Relapse in Pouchitis.

The dynamic trajectory of circulating exosome components in high-fat diet-induced metabolic-associated steatotic liver disease and its modulation by curcuminoids.

Proteolytic remodeling by Yme1 enables mitochondrial-derived compartment formation.

Genetically predicted ZDHHC8 expression and osteoporosis risk: A two-sample Mendelian randomization and metabolite mediation study.

Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Oxidative Stress as a Pathophysiological Core of Obesity: Preclinical Evidence for Antioxidant-Based Therapy Strategies.

Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.

Related Experiment Videos

Circulation times in the splanchnic and hepatic beds in alcoholic liver disease

Related Concept Videos

Related Articles